Schering AG/Epix Contrast Agent Vasovist Gains EU Approval, Waits For FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Vasovist (formerly MS-235) has a U.S. user fee date of Nov. 23; FDA had requested efficacy data from new clinical trials.